IZMYND8-34
IZMYND8-34 is a histone reader ZMYND8 inhibitor that inhibits ZMYND8's histone recognition. iZMYND8-34 can be used for the research of neuroendocrine prostate cancer[1].
Product Specifications
CAS Number
[1358901-59-3]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Zinc Finger Protein
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.89
Solubility
DMSO : 10 mg/mL (ultrasonic)
Smiles
O=C(C1=C2N(C)C(N(C3=CC=C(OCO4)C4=C3)C2=NC(C5=CC=CC(OCC)=C5O)=N1)=O)N
Molecular Formula
C22H19N5O6
Molecular Weight
449.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Wang H, et, al. Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer. Nat Cancer. 2025 Apr;6 (4) :629-646.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15385266 1 Vial
Lentiviral human NVL sgRNA gene knockout kit - Lentiviral human NVL sgRNA gene knockout kit (25)
Ask
View Details 